The efficacy of CP's chelator polymers for anti-biofilm treatment

Chelation Partners（CP）Co.开发了高效的铁结合聚合物分子，可以去除生物学上可用的铁，使病原体对抗生素的敏感性提高数千倍。例如，CP开发了螯合剂DIBI，其在实验室培养中有效抑制革兰氏阳性菌、革兰氏阴性菌和真菌的生长。然而，众所周知，许多细菌都会形成生物膜，其中包含一组相互粘附并嵌入自产的基于细胞外聚合物的基质中的细菌细胞。在生物膜中生长的细菌细胞不同于同一生物体的增殖细胞，后者是在液体培养基中自由移动的单细胞。生物被膜中细菌的显著差异是它们对抗生素的耐药性比抗生素高得多，因此，需要开发能够使生物被膜对抗生素敏感的技术。由于铁对生物膜生长至关重要，CP假设螯合剂DIBI可能有效地使生物膜对抗生素治疗敏感。这个项目是为了用实验证据来验证这个想法。在项目中获得的知识对于CP探索其产品的全部价值并决定如何将结果纳入其产品流非常重要。

Chelation Partners (CP) Co. develops highly efficient iron-binding polymer molecules that remove biologicallyavailable iron, making pathogens thousands of times more susceptible to antibiotics. For example, CPdeveloped the chelator DIBI, which is effective in inhibiting the growth of Gram-positive bacteria,Gram-negative bacteria, and fungi in laboratory culture. However, many bacteria are well known to formbiofilms, which contains group of bacteria cells sticking to each other and embedded within a self-producedextracellular polymeric substance-based matrix. The bacterial cells growing in a biofilm are different fromplanktonic cells of the same organism, which are free-moving single cells in a liquid medium. The strikingdifference of the bacteria in a biofilm is their much higher resistance to antibiotics than the planktonic ones.Therefore, it would be desirable to develop technology that can sensitize the biofilm to antibiotics. Since iron iscritical for biofilm growth, CP hypothesizes that the chelators DIBI may be effective to sensitize biofilmtowards antibiotic treatment. This project is proposed to test the idea with experimental evidence. Theknowledge obtained in the project is important for CP to explore the full value of its product and make decisionon how to incorporate the results into its product streams.